New facility for Bio-Manguinhos will use iBio’s plant-based protein expression technology, iBioLaunch, and GE Healthcare’s expertise in process design and start-to-finish biopharmaceutical and vaccine manufacturing technologies.
GE Healthcare enterprise solutions general manager Olivier Loeillot said, "GE Healthcare’s global capabilities and industry-leading expertise in biopharmaceutical manufacturing technologies, coupled with iBio’s innovative technology and experience in plant-based protein expression, provide a solid foundation for this design project."
Bio-Manguinhos/Fiocruz acts as a manufacturer of immunobiologicals for public health needs basically supporting Brazilian Ministry of Health programs.
Bio-Manguinhos/Fiocruz director Artur Couto said, "The agreement with GE Healthcare is important because it will allow us to build a new facility based on a very innovative platform and address an important need of the Brazilian Ministry of Health."